Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | FPR3 | P25089 | 2/20 | 0.47 |
| ▸ | TSPO | P30536 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557259 | 0.91 | CRHR1 (0.66) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7554726 | 0.91 | CRHR1 (0.64) | CRHR1TDP1 | |
| SCHEMBL7554871 | 0.89 | CRHR1 (0.69) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7563114 | 0.89 | CRHR1 (0.62) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7559415 | 0.88 | CRHR1 (0.70) | CRHR1TDP1 | |
| SCHEMBL7960908 | 0.88 | CRHR1 (0.61) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7553858 | 0.86 | CRHR1 (0.64) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7557736 | 0.85 | CRHR1 (0.61) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL245417 | 0.84 | CRHR1 (0.56) | CRHR1TDP1 | |
| SCHEMBL7555695 | 0.83 | CRHR1 (0.59) | CRHR1TDP1FPR3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | claimed |
| US-20230181673-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2683698-B1 | BENZYL-OXATHIAZINE DERIVATES SUBSTITUTED WITH ADAMANTANE OR NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI SA (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2203415-B1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2203416-B1 | (CARBOXY ALKYLENE-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2144885-B1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2016-06-29 | — | — | EP | disclosed |
| EP-2144891-B1 | 5-OXO-ISOXAZOLES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
| WO-2003084923-A1 | ACYL-3-CARBOXYPHENYLUREA DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084922-A1 | ACYL-4-CARBOXYPHENYLUREA DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2003020269-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003018024-A1 | COMBINED PREPARATIONS, CONTAINING 1,4-BENZOTHIEPINE-1,1-DIOXIDE DERIVATIVES AND OTHER ACTIVE SUBSTANCES, AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-06 | — | — | WO | disclosed |
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6284766-B1 | DIAGNOSIS, THERAPY OF STRESS DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | CRHR1 3283/4885TDP1 1434/4885FPR3 2015/4885 |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | ADRA1D, ADRA1B, ADRB3 | CRHR1 585/4885TDP1 4050/4885FPR3 381/4885 |
| US-20020019406-A1 | 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands | HTR1D, CRHR1, HTR1A | CRHR1 2/4885TDP1 2969/4885FPR3 224/4885 |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | CPS1, AGPAT2, GLS | CRHR1 4699/4885TDP1 3306/4885FPR3 1847/4885 |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | SULT1E1, BPNT1, CYP3A4 | CRHR1 900/4885TDP1 1083/4885FPR3 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.